NCT01331993View on ClinicalTrials.gov

A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Healthy VolunteersBioequivalence
Interventions
DRUG

VIMOVO (AstraZeneca)

VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole

DRUG

VIMOVO (Patheon)

VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole

DRUG

Marketed enteric-coated naproxen formulation

Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY